AnorMed Completes Patient Recruitment To Test MOZOBIL In Stem Cell Transplant For Multiple Myeloma
Filed in archive Drugs, Vaccines and Therapeutics , Stem Cells by ruth on July 11, 2006

According to the Special Protocol Assessment with the FDA,
the most recently enrolled patients will undergo their transplants over the next 4-6 weeks with a subsequent 100 day follow-up period required. The MM trial design also allows physicians to request, upon enrollment, that a patient has the option to have a second or "tandem" transplant should they not go into complete remission. Physicians have up to 6 months from the first transplant to perform a second transplant if required. The 100 day follow-up period would then commence from the date of the second transplant. The results of the study will be unblinded once all patients enrolled have completed their 100 day follow-up.
AnorMed is also still recruiting patients to test MOZOBIL for treating non-Hodgkin's lymphoma
(NHL).For more details, see AnorMed's press release.
Permalink: AnorMed Completes Patient Recruitment To Test MOZOBIL In Stem Cell Transplant For Multiple Myeloma
Tags:
stemcell myeloma stem biotech cell stem+cell cell+transplant mozobil+stem
Trackback: http://www.creative-weblogging.com/cgi-bin/mt-tb.pl/28954







